Results from a phase I study of 4-<i>l</i>-[131I]iodo-phenylalanine ([<sup>131</sup>I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1).Tools Pichler, Josef, Traub-Weidinger, Tatjana, Spiegl, Kurt, Imamovic, Larisa, Braat, Arthur J A T, Snijders, Tom J, Verhoeff, Joost J C, Flamen, Patrick, Tauchmanova, Libuse, Hayward, Colin und Kluge, Andreas (2024) Results from a phase I study of 4-<i>l</i>-[131I]iodo-phenylalanine ([<sup>131</sup>I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1). Neuro-oncology advances, 6 (1). vdae130. ISSN 2632-2498 Vorschau Pichler Results from a phase I study IPAX-1 Neurooncol Advanc 2024.pdf Download (481kB) | Vorschau KurzfassungGlioblastoma (GBM), the most common malignant brain tumor, is associated with devastating outcomes. IPAX-1 was a multicenter, open-label, single-arm phase I study to evaluate carrier-added 4-<i>L</i>-[<sup>131</sup>I]iodo-phenylalanine ([<sup>131</sup>I]IPA) plus external radiation therapy (XRT) in recurrent GBM.
Actions (login required)
|
||||||||||||||||
 |
|
|
Tools
Tools
